Exciton Technologies receives FDA approval to market exSALT(TM)
“This achievement represents a significant team effort and a strong belief in our product,” stated
The global wound-care market was
- Utilizing a more active form of silver; - Reducing costs; and - Being amendable to more applications such as consumer products, catheters and orthopedic devices. About exSALT(TM) ----------------
Silver has powerful antimicrobial properties. In the proper chemical form, it is proven as a highly effective wound-care agent with important benefits for promoting healing and preventing infection. Exciton’s exSALT(TM) antimicrobial technology uses a patented chemical deposition technique to form a coating of active species of silver on a wide range of materials. The exSALT(TM) SD7 Wound Dressing targets the advanced wound care market in preventing infection during the treatment of burn and chronic wounds such as diabetic foot ulcers and bed sores. By adjusting the dose of silver and expanding the number of product configurations, Exciton can target a greater portion of the overall market.
About Exciton Technologies Inc. -------------------------------
Exciton Technologies Inc. is an
Forward-looking Statements --------------------------
This press release may contain forward-looking statements. Forward looking statements, including the Company’s belief as to the potential of its products, the Company’s expectations regarding the issuance of additional patents and the Company’s ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company’s patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company’s quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.
SOURCE Exciton Technolgies Inc.